GLOW Peptide Blend in New Zealand: What's In It (Research Guide)

The short answer

GLOW is a name used by suppliers for a multi-peptide research blend. It most commonly combines three research peptides in a single vial: GHK-Cu, a copper-binding tripeptide, together with BPC-157 and TB-500. The exact ratio varies by supplier, but a frequently listed format pairs a larger amount of GHK-Cu with smaller amounts of BPC-157 and TB-500. In New Zealand, the individual peptides in a GLOW blend are prescription-only scheduled substances, and none are approved for general therapeutic use. Products sold under this name are supplied strictly for laboratory research use only.

What is the GLOW blend?

GLOW is a supplier coined name rather than a defined pharmaceutical product. There is no single official formula, no standard dose and no regulatory monograph for a product called GLOW. Different vendors assemble the blend in different ratios, so two vials labelled GLOW may not contain the same amounts.

Across the market, the blend is usually built from three research peptides combined in one vial. A commonly listed configuration places the copper peptide GHK-Cu as the largest component, with BPC-157 and TB-500 added in smaller amounts. Independent testing of individual batches has at times shown figures that differ from the printed label, which is one reason researchers treat any supplier stated composition as a claim to verify rather than a certainty.

Peptides typically found in a GLOW blend

• GHK-Cu, a copper-binding tripeptide
• BPC-157, a synthetic pentadecapeptide
• TB-500, a synthetic fragment related to thymosin beta-4

GHK-Cu, the copper peptide

GHK-Cu stands for glycyl-L-histidyl-L-lysine bound to copper. It is a naturally occurring tripeptide that forms a complex with a copper ion, and it is usually the largest component by mass in a GLOW blend. In the scientific literature it is studied mainly in the context of the extracellular matrix and collagen, and much of the published human work involves topical cosmetic formulations rather than injectable preparations. In a research setting it is examined as a model copper-peptide complex, with literature interest centred on how copper peptides interact with matrix proteins. This guide does not describe any use in people and makes no claim about skin, ageing, healing or appearance.

BPC-157 in the blend

BPC-157 is a synthetic peptide of fifteen amino acids, which is why it is sometimes called a pentadecapeptide. Its sequence is derived from a portion of a protein found in gastric juice. The overwhelming majority of published research on BPC-157 is preclinical, meaning it comes from laboratory and animal studies rather than controlled human trials, and reviews of the literature note that tissue related findings remain largely unvalidated in humans. It is the component of the GLOW blend most often discussed in connection with regulatory attention. In July 2026 it was among several peptides reviewed by regulators overseas in the context of pharmacy compounding, a process that concerns how licensed pharmacies may prepare substances under prescription rather than whether any blend is approved for sale.

TB-500 in the blend

TB-500 is a synthetic peptide fragment modelled on thymosin beta-4, a naturally occurring protein involved in regulating actin, a structural component inside cells. TB-500 and thymosin beta-4 are generally presumed to share similar properties by design. Published studies examine its role in cell migration and actin binding in laboratory models, and, as with BPC-157, the available research is largely preclinical rather than based on controlled human trials. Regulators in New Zealand treat TB-500 and thymosin beta-4 together for scheduling purposes.

Regulatory status in New Zealand

Because GLOW is a blend, its status in New Zealand is determined by the status of each peptide it contains. All three are handled under the Poisons Standard, also known as the SUSMP, which is administered by the Therapeutic Goods Administration (TGA).

Component status in New Zealand

• BPC-157 is listed in Schedule 4 (prescription only) and in Appendix D of the Poisons Standard. It is not entered on the New Zealand Register of Therapeutic Goods (ARTG) and is not approved for therapeutic use.
• TB-500 and thymosin beta-4 are addressed by Schedule 4 and Appendix D entries in the Poisons Standard and are likewise not approved for therapeutic use.
• GHK-Cu is treated as a prescription substance in injectable form, while topical cosmetic uses are regulated differently. It is not approved as an injectable therapeutic product.

The TGA has publicly named BPC-157, TB-500, GHK-Cu and other peptides as examples of unapproved products, meaning they have not been assessed by the TGA for quality, safety or efficacy for human use. Appendix D adds extra controls on top of ordinary Schedule 4 status. Anyone handling these substances should confirm the current entries directly against the Poisons Standard, as scheduling can change over time.

WADA and sport

The two tissue related peptides in a GLOW blend are relevant to anti-doping. BPC-157 is referenced on the WADA Prohibited List, and thymosin beta-4 and its derivatives, which include TB-500, fall within the growth factors area of the list. Sport Integrity New Zealand, which aligns with the WADA framework, also lists these peptides as prohibited substances. This means they are banned for athletes who compete under anti-doping rules. The sporting status is separate from, and additional to, the TGA scheduling described above.

Research use only

Products sold under the GLOW name on this site are supplied strictly for laboratory and research use only. They are not medicines, are not for human or veterinary use, and are not intended to diagnose, treat, cure or prevent any condition. Nothing on this page is a dosing guide or a protocol.

If you are researching a GLOW style blend, the most useful starting point is accurate information about each component, a clear understanding of its New Zealand scheduling, and documentation such as a certificate of analysis for the specific batch. Because supplier stated ratios can differ from independent testing, treat composition figures as claims to be verified. For questions about legal status or health, speak with a qualified professional.

Frequently asked questions